Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Nektar Therapeutics (NKTR) and Bristol Myers Squibb (BMY) announced the discontinuation of the global clinical development program for bempegaldesleukin in combination with Opdivo after late-stage studies failed to show clinical benefit in renal cell carcinoma and bladder cancer. In the Phase 3 PIVOT-09 study, bempegaldesleukin did not meet the criteria for statistical significance compared to the TKI control arm. The separate Phase 2 PIVOT-10 study also lacked sufficient efficacy. All related studies will be terminated, allowing patients to pursue standard treatment options.
Bristol Myers Squibb announced the Phase 3 CheckMate -816 trial results, showing that Opdivo (nivolumab) combined with chemotherapy significantly improved event-free survival (EFS) for resectable non-small cell lung cancer (NSCLC). Administering three cycles of Opdivo before surgery reduced the recurrence, progression, or death risk by 37%. The median EFS was 31.6 months for the combination compared to 20.8 months for chemotherapy alone. Opdivo received FDA approval for this neoadjuvant treatment based on these findings. Early overall survival trends were also promising, with 83% alive at two years.
Bristol Myers Squibb has received Marketing Authorization from the European Commission for Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy designed for adults with relapsed or refractory large B-cell lymphoma. This approval is based on outcomes from the TRANSCEND trials, demonstrating a 73% response rate and a manageable safety profile. The approval marks the company's second CAR T therapy in the EU, expanding treatment options for patients facing limited choices. Breyanzi aims to address unmet medical needs in this patient population.
Bristol Myers Squibb has announced that the European Commission has approved Opdivo (nivolumab) combined with chemotherapy as a first-line treatment for adults with unresectable advanced esophageal squamous cell carcinoma (ESCC) with PD-L1 expression ≥ 1%. This approval is based on the Phase 3 CheckMate -648 trial, which showed a median overall survival of 15.44 months for Opdivo plus chemotherapy versus 9.07 months for chemotherapy alone. The safety profile aligns with previous studies, marking a significant advancement for patients in the EU.
Bristol Myers Squibb has received European Commission approval for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression ≥ 1%. The approval follows results from the Phase 3 CheckMate-648 trial, highlighting a median overall survival of 13.70 months for patients treated with Opdivo plus Yervoy, compared to 9.07 months with chemotherapy. This treatment is now available in the EU, Iceland, Liechtenstein, and Norway.
Bristol Myers Squibb announced that the European Commission approved Opdivo (nivolumab) for adjuvant treatment of adults with muscle-invasive urothelial carcinoma, marking it as the first immunotherapy option approved in this setting in the EU. The approval is based on Phase 3 CheckMate -274 trial results, showing a 47% reduction in the risk of disease recurrence or death for patients with PD-L1 expression ≥1%, compared to placebo. Opdivo has now received EU approvals for three cancer types, enhancing its position in cancer treatment.
Bristol Myers Squibb (NYSE: BMY) announced favorable interim results from the EXPLORER-LTE cohort of the MAVA-LTE study, revealing sustained improvements in cardiac measures at 48 and 84 weeks for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Key findings include a decrease in left ventricular outflow tract (LVOT) gradients and NYHA Class improvements in 67.5% of patients. The safety profile remained stable with no new adverse signals. The company anticipates FDA feedback on its New Drug Application by the end of the month.
Bristol Myers Squibb (NYSE: BMY) announced positive results from the Phase 3 VALOR-HCM study of mavacamten, a first-in-class cardiac myosin inhibitor. The study met all primary and secondary endpoints, demonstrating significant improvements in patients with symptomatic obstructive hypertrophic cardiomyopathy after 16 weeks. Notably, 82% of patients treated with mavacamten did not require septal reduction therapy, compared to only 23% in the placebo group. Safety data showed no new signals, validating mavacamten's efficacy as a potential treatment option.
Bristol Myers Squibb has announced the European Medicines Agency's validation of its application for Opdivo in combination with chemotherapy for neoadjuvant treatment of resectable stage IB to IIIA non-small cell lung cancer (NSCLC). This regimen aims to be the first immunotherapy-based option before surgery in the EU, based on results from the CheckMate-816 trial, which showed significant improvements in event-free survival and pathologic complete response. Opdivo's safety profile remains consistent with previous studies.
Bristol Myers Squibb (NYSE: BMY) announced an extension of the FDA review for the supplemental biologics license application (sBLA) of Reblozyl (luspatercept-aamt), treating anemia in adults with non-transfusion-dependent beta thalassemia, now due by